PFE Pfizer Inc

31.96
0  0%
Previous Close 0.00
Open 0.00
Price To book 0.00
Market Cap
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date August 27, 2017 under priority review.
Avelumab
Urothelial Carcinoma
Priority review announced February 21, 2016. Estimate PDUFA date August 21, 2017 at latest. Possibly earlier as NDA acceptance was announced following 3-day weekend.
Inotuzumab Ozogamicin
Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults
Phase 2 positive data released January 26, 2017. Phase 3 trial to commence 1H 2017.
PF-06425090
C. difficile Infection
Phase 3 ongoing. Estimate data 1H 2019 using clinicaltrials.gov data.
XTANDI (ENDEAR)
Triple negative breast cancer
Phase 3 ongoing. Estimate data 2020 using clinicaltrials.gov data.
XTANDI
Metastatic hormone sensitive prostate cancer
Phase 3 ongoing. Estimate data 1H 2021 using clinicaltrials.gov data.
XTANDI (EMBARK)
Non-metastatic high risk hormone-sensitive prostate cancer
Phase 3 completed. Regulatory filing due 1H 2017.
Xeljanz
Psoriatic arthritis
Phase 3 completed. Regulatory filing due 1H 2017.
Xeljanz
Ulcerative colitis
Phase 3 ongoing. Estimate data due late 2017 or early 2018 using clinicaltrials.gov data.
Tanezumab
Chronic low back pain
Phase 3 ongoing. Estimate data due 2018 using clinicaltrials.gov data.
Tanezumab
Cancer pain
Phase 3 ongoing. Estimate data late 2017 or early 2018 using clinicaltrials.gov data.
Tanezumab
Osteoarthritis
Phase 3 data due 2017. Estimate 2H 2017 using clinicaltrials.gov data.
Talazoparib (EMBRACA)
BRCA-mutated breast cancer
Phase 3 primary endpoint met - July 2016.
Sutent (Sunitinib)
Renal cell carcinoma (RCC)
Phase 3 trial met primary endpoint - December 2016.
LYRICA (pregabalin)
Pediatric Epilepsy
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP (MOD-4023)
Adults - growth hormone deficiency
Phase 3 initiation announced December 30, 2016.
hGH-CTP (MOD-4023)
Children - growth hormone deficiency
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
Ertugliflozin
Type 2 diabetes
Phase 3 initiated June 2015. Enrollment to be completed 2H 2018.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Phase 3 trial met primary endpoint - December 2016.
BOSULIF (BFORE)
First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Priority review announced November 29, 2016. Approval announced March 23, 2017.
Avelumab
Metastatic Merkel cell carcinoma
sNDA acceptance announced December 21, 2016. Approval announced March 31, 2017.
IBRANCE (palbociclib)
HR+, HER2- Metastatic Breast Cancer

Latest News

  1. If You're in Your 50s, Consider Buying These 3 Stocks
  2. Trump Executive Order Could Revive Allergan-Pfizer Merger
  3. Better Buy: AbbVie Inc. vs. Pfizer
  4. FDA OKs Samsung Bioepis’s Biosimilar Version Of J&J’s Remicade
  5. Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
  6. Making Drug Manufacturing Great Again
  7. Pfizer Unveils ATLAS®, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Across 60 Countries
  8. Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders
  9. Bristol-Myers Squibb Co: Buy the Dip?
  10. 3 Top High-Yield Dividend Stocks to Buy Now
  11. Pfizer subpoenaed in U.S. intravenous saline solution probe
  12. Pfizer Follows Baxter, Gets Slammed With Subpoena Related To Saline Shortage
  13. Is J&J's Pharma Sales Slowdown a Warning for Other Players?
  14. Pfizer is latest to get Justice Department subpoena in intravenous saline investigation
  15. Pfizer Inc. – Value Analysis (NYSE:PFE) : April 19, 2017
  16. Gilead Sciences: Who's Frustrated Now?
  17. Why Is Pfizer (PFE) Up 8.7% Since the Last Earnings Report?
  18. Johnson & Johnson Sees Little Impact In Key Area Despite Pfizer Competition
  19. High-Yield Healthcare Investments You Can Buy Right Now
  20. Johnson & Johnson says pricing competition squeezed 1Q sales